NASDAQ:HZNP

Horizon Therapeutics Public Stock Forecast, Price & News

$90.91

+0.34 (+0.38 %)

(As of 02/26/2021 12:00 AM ET)

Add

Compare

Today's Range

$89.77

Now: $90.91▼

$93.30

50-Day Range

$71.83

MA: $82.35▼

$95.48

52-Week Range

$23.81

Now: $90.91▼

$96.54

Volume3.11 million shs

Average Volume2.10 million shs

Market Capitalization$20.06 billion

P/E Ratio24.84

Dividend YieldN/A

Beta1.15

Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing of medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of rheumatoid arthritis (RA), polymyalgia rheumatic, systemic lupus erythematosus, and various other indications; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company also offers PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis (OA) of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; and VIMOVO for the relief of signs and symptoms of OA, RA, and ankylosing spondylitis to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers. It has collaboration agreements with Lupus Research and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Headlines

Horizon Therapeutics plc to Present at the Cowen and Company 41st Annual Health Care Conference
February 26, 2021 | finance.yahoo.com

Why Horizon Therapeutics Stock Jumped Today
February 25, 2021 | msn.com

Why Horizon Therapeutics's Stock is Trading Higher Today
February 24, 2021 | msn.com

Horizon Posts Triple-Digit Sales Growth After Adding Tepezza To Lineup
February 24, 2021 | finance.yahoo.com

Horizon Therapeutics plc Reports Record Fourth-Quarter and Full-Year 2020 Financial Results; Announces Full-Year 2021 Guidance
February 24, 2021 | finance.yahoo.com

Horizon's 'Breakthrough Year' Ends With Fourth-Quarter Earnings Beat
February 24, 2021 | finance.yahoo.com

New Survey Assessment Finds Debilitating Impact of Thyroid Eye Disease (TED) on Quality of Life Continues Well Beyond Acute Disease into Chronic Phase
February 22, 2021 | finance.yahoo.com

Horizon Therapeutics (HZNP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
February 19, 2021 | msn.com

Inovio Pharmaceuticals Shows Market Leadership With Jump To 86 RS Rating
February 18, 2021 | finance.yahoo.com

Horizon Pharma Shows Rising Price Performance With Jump To 85 RS Rating
February 3, 2021 | finance.yahoo.com

Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2020 Financial Results and Host Webcast on Feb. 24, 2021
February 3, 2021 | finance.yahoo.com

SHAREHOLDER ALERT: WeissLaw LLP Investigates Viela Bio, Inc.
February 1, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNASDAQ:HZNP

Previous Symbol

CUSIP44047T10

CIK1492426

Webwww.horizontherapeutics.com

Phone011-353-1772-2100

Employees1,275

Year Founded2008

Debt

Debt-to-Equity Ratio0.26

Current Ratio3.49

Quick Ratio3.39

Price-To-Earnings

Trailing P/E Ratio24.84

Forward P/E Ratio28.32

P/E Growth0.59

Sales & Book Value

Annual Sales$1.30 billion

Price / Sales15.43

Cash Flow$4.09 per share

Price / Cash Flow22.22

Book Value$11.67 per share

Price / Book7.79

Profitability

EPS (Most Recent Fiscal Year)$1.94

Net Income$573.02 million

Net Margins43.55%

Return on Equity25.66%

Return on Assets14.19%

Miscellaneous

Outstanding Shares220,710,000

Market Cap$20.06 billion

Next Earnings Date5/5/2021 (Estimated)

OptionableOptionable

MarketRank^™

Overall MarketRank^™

2.37 out of 5 stars

Medical Sector

17th out of 1,962 stocks

Pharmaceutical Preparations Industry

8th out of 772 stocks

2.5 Analyst's Opinion

Consensus Rating
Horizon Therapeutics Public has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $101.89, Horizon Therapeutics Public has a forecasted upside of 12.1% from its current price of $90.91.
Amount of Analyst Coverage
Horizon Therapeutics Public has only been the subject of 1 research reports in the past 90 days.

3.3 Community Rank

Outperform Votes
Horizon Therapeutics Public has received 851 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Horizon Therapeutics Public has received 435 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Horizon Therapeutics Public has received 66.17% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics Public and other stocks. Vote “Outperform” if you believe HZNP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Horizon Therapeutics Public does not currently pay a dividend.
Dividend Growth
Horizon Therapeutics Public does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Horizon Therapeutics Public insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,227,857.00 in company stock.
Percentage Held by Insiders
Only 4.30% of the stock of Horizon Therapeutics Public is held by insiders.
Percentage Held by Institutions
88.59% of the stock of Horizon Therapeutics Public is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

4.4 Earnings and Valuation

Earnings Growth
Earnings for Horizon Therapeutics Public are expected to grow by 33.96% in the coming year, from $3.21 to $4.30 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Horizon Therapeutics Public is 24.84, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 32.52.
Price to Earnings Ratio vs. Sector
The P/E ratio of Horizon Therapeutics Public is 24.84, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 40.57.
Price to Earnings Growth Ratio
Horizon Therapeutics Public has a PEG Ratio of 0.59. PEG Ratios below 1 indicate that a company could be undervalued.
Price to Book Value per Share Ratio
Horizon Therapeutics Public has a P/B Ratio of 7.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$90.91

+0.34 (+0.38 %)

(As of 02/26/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive HZNP News and Ratings via Email

Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter.

Horizon Therapeutics Public (NASDAQ:HZNP) Frequently Asked Questions

Is Horizon Therapeutics Public a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics Public in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Horizon Therapeutics Public stock.
View analyst ratings for Horizon Therapeutics Public or view top-rated stocks.

What stocks does MarketBeat like better than Horizon Therapeutics Public?

Wall Street analysts have given Horizon Therapeutics Public a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Horizon Therapeutics Public wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Horizon Therapeutics Public?

Horizon Therapeutics Public saw a decrease in short interest in January. As of January 15th, there was short interest totaling 5,950,000 shares, a decrease of 20.0% from the December 31st total of 7,440,000 shares. Based on an average daily trading volume, of 2,630,000 shares, the short-interest ratio is presently 2.3 days.
View Horizon Therapeutics Public's Short Interest.

When is Horizon Therapeutics Public's next earnings date?

Horizon Therapeutics Public is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Horizon Therapeutics Public.

How were Horizon Therapeutics Public's earnings last quarter?

Horizon Therapeutics Public Limited (NASDAQ:HZNP) posted its quarterly earnings results on Tuesday, February, 23rd. The biopharmaceutical company reported $1.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.06 by $0.22. Horizon Therapeutics Public had a trailing twelve-month return on equity of 25.66% and a net margin of 43.55%.
View Horizon Therapeutics Public's earnings history.

How has Horizon Therapeutics Public's stock price been impacted by COVID-19 (Coronavirus)?

Horizon Therapeutics Public's stock was trading at $30.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HZNP stock has increased by 198.0% and is now trading at $90.91.
View which stocks have been most impacted by COVID-19.

What guidance has Horizon Therapeutics Public issued on next quarter's earnings?

Horizon Therapeutics Public issued an update on its FY 2021 Pre-Market earnings guidance on Wednesday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.7-2.8 billion, compared to the consensus revenue estimate of $2.68 billion.

What price target have analysts set for HZNP?

8 equities research analysts have issued 1 year price targets for Horizon Therapeutics Public's stock. Their forecasts range from $85.00 to $120.00. On average, they expect Horizon Therapeutics Public's share price to reach $101.89 in the next year. This suggests a possible upside of 12.1% from the stock's current price.
View analysts' price targets for Horizon Therapeutics Public or view top-rated stocks among Wall Street analysts.

Who are Horizon Therapeutics Public's key executives?

Horizon Therapeutics Public's management team includes the following people:

Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 54, Pay $4.73M)
Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 56, Pay $1.67M)
Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 67, Pay $1.46M)
Mr. Vikram Karnani, Exec. VP & Pres of International (Age 46, Pay $1.34M)
Mr. Miles W. McHugh, Chief Accounting Officer & Sr. VP (Age 56)
Dr. Karin Rosen M.D., Ph.D., Exec. VP of R&D and Chief Scientific Officer
Ms. Tina E. Ventura, Sr. VP of Investor Relations
Mr. Brian K. Beeler, Exec. VP & Gen. Counsel (Age 48)
Mr. Timothy Ayers, Chief Compliance Officer & VP
Mr. Geoffrey M. Curtis, Exec. VP of Corp. Affairs & Chief Communications Officer (Age 46)

What is Timothy Walbert's approval rating as Horizon Therapeutics Public's CEO?

70 employees have rated Horizon Therapeutics Public CEO Timothy Walbert on Glassdoor.com. Timothy Walbert has an approval rating of 73% among Horizon Therapeutics Public's employees.

Who are some of Horizon Therapeutics Public's key competitors?

Some companies that are related to Horizon Therapeutics Public include Johnson & Johnson (JNJ), Eli Lilly and (LLY), AbbVie (ABBV), Pfizer (PFE), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT), Endo International (ENDP) and Supernus Pharmaceuticals (SUPN).
View all of HZNP's competitors.

What other stocks do shareholders of Horizon Therapeutics Public own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics Public investors own include Alibaba Group (BABA), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), Netflix (NFLX), Gilead Sciences (GILD), Tesla (TSLA), AbbVie (ABBV), Micron Technology (MU) and PayPal (PYPL).

What is Horizon Therapeutics Public's stock symbol?

Horizon Therapeutics Public trades on the NASDAQ under the ticker symbol "HZNP."

Who are Horizon Therapeutics Public's major shareholders?

Horizon Therapeutics Public's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.44%), FMR LLC (6.00%), Avoro Capital Advisors LLC (4.08%), Janus Henderson Group PLC (3.71%), Renaissance Technologies LLC (3.08%) and JPMorgan Chase & Co. (2.68%). Company insiders that own Horizon Therapeutics Public stock include Barry Moze, Brian K Beeler, Daniel A Camardo, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani.
View institutional ownership trends for Horizon Therapeutics Public.

Which major investors are selling Horizon Therapeutics Public stock?

HZNP stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Renaissance Technologies LLC, Dimensional Fund Advisors LP, Price T Rowe Associates Inc. MD, Janus Henderson Group PLC, William Blair Investment Management LLC, Emerald Advisers LLC, and Emerald Mutual Fund Advisers Trust. Company insiders that have sold Horizon Therapeutics Public company stock in the last year include Barry Moze, Brian K Beeler, Daniel A Camardo, Irina Konstantinovsky, Jeff Kent, Jeffrey W Sherman, Michael A Desjardin, Michael G Grey, Miles W Mchugh, Paul W Hoelscher, Timothy P Walbert, and Vikram Karnani.
View insider buying and selling activity for Horizon Therapeutics Public or view top insider-selling stocks.

Which major investors are buying Horizon Therapeutics Public stock?

HZNP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Viking Global Investors LP, Avoro Capital Advisors LLC, JPMorgan Chase & Co., Clearbridge Investments LLC, Thornburg Investment Management Inc., C WorldWide Group Holding A S, and Wells Fargo & Company MN.
View insider buying and selling activity for Horizon Therapeutics Public or or view top insider-buying stocks.

How do I buy shares of Horizon Therapeutics Public?

Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Horizon Therapeutics Public's stock price today?

One share of HZNP stock can currently be purchased for approximately $90.91.

How much money does Horizon Therapeutics Public make?

Horizon Therapeutics Public has a market capitalization of $20.06 billion and generates $1.30 billion in revenue each year. The biopharmaceutical company earns $573.02 million in net income (profit) each year or $1.94 on an earnings per share basis.

How many employees does Horizon Therapeutics Public have?

Horizon Therapeutics Public employs 1,275 workers across the globe.

Does Horizon Therapeutics Public have any subsidiaries?

The following companies are subsidiares of Horizon Therapeutics Public: Andromeda Biotech Limited, Curzion Pharmaceuticals Inc., HZNP Canada Limited, HZNP Finance Limited, HZNP Limited, HZNP USA LLC, Horizon Medicines LLC, Horizon Ophthalmology Inc, Horizon Orphan Holdings LLC, Horizon Orphan LLC, Horizon Pharma Aon Limited, Horizon Pharma Dó Limited, Horizon Pharma Israel Holding Corp. Ltd, Horizon Pharma Rheumatology LLC, Horizon Pharma Trí Limited, Horizon Therapeutics Capital Limited, Horizon Therapeutics Finance Limited, Horizon Therapeutics Finance S.à.r.l, Horizon Therapeutics GmbH, Horizon Therapeutics Holdings Limited, Horizon Therapeutics Investment Limited, Horizon Therapeutics Ireland DAC, Horizon Therapeutics LLC, Horizon Therapeutics Schweiz GmbH, Horizon Therapeutics Services LLC, Horizon Therapeutics Treasury DAC, Horizon Therapeutics USA Inc., Hyperion Therapeutics Ireland Holding Limited, Hyperion Therapeutics Ireland Operating Limited, and River Vision Development Corp..

When was Horizon Therapeutics Public founded?

Horizon Therapeutics Public was founded in 2008.

What is Horizon Therapeutics Public's official website?

The official website for Horizon Therapeutics Public is www.horizontherapeutics.com.

Where are Horizon Therapeutics Public's headquarters?

Horizon Therapeutics Public is headquartered at 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6.

How can I contact Horizon Therapeutics Public?

Horizon Therapeutics Public's mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected]

This page was last updated on 2/28/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here